Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1422809

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1422809

Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2024-2032

PUBLISHED:
PAGES: 139 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3899
PDF & Excel (5 User License)
USD 4899
PDF & Excel (Corporate License)
USD 5899

Add to Cart

Abstract

The global human chorionic gonadotropin (HCG) market size reached US$ 973.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.

Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.

Human Chorionic Gonadotropin (HCG) Market Trends:

The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human chorionic gonadotropin (HCG) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, therapeutic area, and end user.

Technology Insights:

Natural Source Extraction

Recombinant Technology

The report has also provided a detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the technology. This includes natural source extraction and recombinant technology. According to the report, natural source extraction represented the largest segment.

Therapeutic Area Insights:

Female Infertility Treatment

Male Hypogonadism

Oligospermic Treatment

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the therapeutic area has been provided in the report. This includes female infertility treatment, male hypogonadism, oligospermic treatment, and others. According to the report, female infertility treatment accounted for the largest market share.

End User Insights:

Fertility Clinics

Research Institutions

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the end user has been provided in the report. This includes fertility clinics, research institutions, and others. According to the report, fertility clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for human chorionic gonadotropin (HCG). Some of the factors driving the North America human chorionic gonadotropin (HCG) market include rising incidences of infertility among women, growing consumer awareness regarding the available treatment for infertility and gynecological concerns, and rising expenditure capacities of consumers.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc.

Key Questions Answered in This Report:

  • How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
  • What are the key regional markets?
  • Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
  • Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?
Product Code: SR112024A7059

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Chorionic Gonadotropin (HCG) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Natural Source Extraction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Recombinant Technology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

  • 7.1 Female Infertility Treatment
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Male Hypogonadism
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oligospermic Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Fertility Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutions
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocare Medical LLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Ferring Pharmaceuticals
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Fresenius SE & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Prospec-Tany Technogene Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Scripps Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sun Pharmaceutical Industries Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
Product Code: SR112024A7059

List of Figures

  • Figure 1: Global: Human Chorionic Gonadotropin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Human Chorionic Gonadotropin Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Human Chorionic Gonadotropin Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 6: Global: Human Chorionic Gonadotropin Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Human Chorionic Gonadotropin Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Human Chorionic Gonadotropin (Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Human Chorionic Gonadotropin (Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Human Chorionic Gonadotropin (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Human Chorionic Gonadotropin (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Human Chorionic Gonadotropin Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Human Chorionic Gonadotropin Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Human Chorionic Gonadotropin Industry: Value Chain Analysis
  • Figure 77: Global: Human Chorionic Gonadotropin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Chorionic Gonadotropin Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 4: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Human Chorionic Gonadotropin Market: Competitive Structure
  • Table 7: Global: Human Chorionic Gonadotropin Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!